6 European Projects Found
Searched on 125080 European Projects
FINISHED
Clinical Studies on a Multivalent Vaccine for Human Visceral Leishmaniasis (MuLeVaClin)
Start date: Nov 1, 2013, End date: Oct 31, 2018,
The World Health Organisation in its report on Neglected Tropical Diseases has stated that there is overwhelming evidence to show that the burden caused by many of the 17 diseases that affect more than 1billion people worldwide can be effectively controlled and, in many cases, eliminated or even eradicated. Leishmaniasis caused by Leishmania spp is one of them and poses a grave health risk to an e ...
Read Project
9
Partners Participants
FINISHED
A “Universal” Influenza Vaccine through Synthetic, Dendritic Cell-Targeted, Self-Replicating RNA Vaccines (UniVax)
Start date: Oct 1, 2013, End date: Sep 30, 2018,
Although vaccination is the cornerstone of prophylaxis, current vaccines provide only moderate protection. Most employ inactivated or protein-based, including multimeric antigen, vaccines requiring annual updating. Their limited antigen loads provide limited capacity for inducing robust immune defences, without assurance that both humoral and cell mediated (CMI) responses, as well as durable immun ...
Read Project
11
Partners Participants
FINISHED
Novel Bone Morphogenetic Protein-6 Biocompatible Carrier Device for Bone Regeneration (OSTEOGROW)
Start date: Jan 1, 2012, End date: Dec 31, 2016,
...s and to determine the final formulation of OSTEOGROW. Clinical trials will start within 18 months from the start of the project funding.Business strategy: SMEs Genera Research, Vitrology Limited and Meditox will test and validate the rhBMP6 production in their facilities. Consortium members from Medical University of Vienna, Sarajevo University Clinical Centre, Linkoping University Faculty of Hea ...
Read Project
11
Partners Participants
FINISHED
Innovative anti-influenza drugs excluding viral escape (ANTIFLU)
Start date: Jun 1, 2011, End date: May 31, 2016,
ANTIFLU is to develop innovative drugs against influenza virus infections based on a novelconcept that precludes the development of viral resistance and ensures efficacy againstupcoming pandemic influenza strains. Viral replication is known to depend on multiple hostfactors. Whilst traditional anti-influenza treatments usually target viral factors, ANTIFLU willaim at drugs interfering with host-re ...
Read Project
11
Partners Participants
FINISHED
Microbicide Optimization Through Innovative Formulation for Vaginal and Rectal Delivery (MOTIF)
Start date: Oct 1, 2012, End date: Mar 31, 2016,
"The 40% protection against HIV-1 infection with vaginally-applied tenofovir gel demonstrated in the CAPRISA004 trial, has emphasized development of anti-retroviral (ARV)-based microbicides. Combining ARVs in a single product may provide increased protection. Development of a generally applicable formulation platform for combining ARVs (even if chemically incompatible) and understanding of the pro ...
Read Project
9
Partners Participants
FINISHED
Development of an oral Helicobacter Pylori vaccine (HELICOVAXOR)
Start date: Oct 1, 2012, End date: Dec 31, 2014,
"Helicobacter pylori infection is highly prevalent worldwide and is an important cause of gastritis, peptic ulcer disease, and significantly gastric cancer. Because eradication requires treatment with multidrug regimens, there exists a very strong need for a vaccine to prevent initial infection.Immunization with H pylori protein subunits in humans has shown adjuvant-related adverse effects and onl ...
Read Project
